Axerion Therapeutics Generally Claimed Allowable Recovery Act Grant Costs
Axerion Therapeutics (the grantee) claimed costs of $951,000 that were allowable under the terms of the grant and applicable Federal regulations; however, the grantee did not account for $54,000 in proceeds that it earned from the sale of equipment that was purchased for the grant. The National Institutes of Health awarded the grantee $3 million under the American Recovery and Reinvestment Act of 2009.
Download the complete report
Adobe® Acrobat® is required to read PDF files.
Let's start by choosing a topic
Unimplemented OIG recommendations summarized.
FY 2014 Work Plan
OIG projects planned for 2014.
Significant OIG activities in 6-month increments.